Feb 29 (Reuters) - Ironwood Pharmaceuticals said on Thursday that its treatment for a type of bowel disease met the main goal in a late-stage trial. (Reporting by Christy Santhosh; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.82 USD | -3.22% | -1.26% | -31.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.64% | 1.24B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood says bowel disease treatment meets main goal in late-stage trial